Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia

doi:10.1002/ajh.26524

. 2022 Jun 1;97(6):E191-E194.

doi: 10.1002/ajh.26524. Epub 2022 Mar 18.

Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia

Affiliations

¹ Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA.
² Department of Medicine, Stanford University, Stanford, California, USA.
³ Department of Medicine, University of California, Davis, California, USA.
⁴ Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, California, USA.
⁵ Section of Hematology/Oncology, Department of Medicine, University of Oklahoma, Oklahoma City, Oklahoma, USA.
⁶ Division of Hematology/Oncology, Department of Medicine, University of California, Davis, California, USA.
⁷ Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, California, USA.
⁸ Division of Hematology, Department of Medicine, Stanford University, Stanford, California, USA.

PMID: 35266185
DOI: 10.1002/ajh.26524

Free article

Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia

Vanessa E Kennedy et al. Am J Hematol. 2022.

Free article

. 2022 Jun 1;97(6):E191-E194.

doi: 10.1002/ajh.26524. Epub 2022 Mar 18.

Authors

Affiliations

¹ Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA.
² Department of Medicine, Stanford University, Stanford, California, USA.
³ Department of Medicine, University of California, Davis, California, USA.
⁴ Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, California, USA.
⁵ Section of Hematology/Oncology, Department of Medicine, University of Oklahoma, Oklahoma City, Oklahoma, USA.
⁶ Division of Hematology/Oncology, Department of Medicine, University of California, Davis, California, USA.
⁷ Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, California, USA.
⁸ Division of Hematology, Department of Medicine, Stanford University, Stanford, California, USA.

PMID: 35266185
DOI: 10.1002/ajh.26524

No abstract available

PubMed Disclaimer

Cited by

Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimetics.
Korell F, Olson ML, Salas-Benito D, Leick MB, Larson RC, Bouffard A, Silva H, Gasparetto A, Berger TR, Kann MC, Mergen M, Kienka T, Wehrli M, Haradhvala NJ, Bailey SR, Letai A, Maus MV. Korell F, et al. Sci Transl Med. 2024 Jun 5;16(750):eadk7640. doi: 10.1126/scitranslmed.adk7640. Epub 2024 Jun 5. Sci Transl Med. 2024. PMID: 38838132 Free PMC article.
The approach of HMA plus VEN with or without BMT for all patients with AML.
Male HJ, Lin TL. Male HJ, et al. Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):186-191. doi: 10.1182/hematology.2023000428. Hematology Am Soc Hematol Educ Program. 2023. PMID: 38066860 Free PMC article.
Trial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: a prospective cohort study.
Wolach O, Levi I, Nachmias B, Tavor S, Amitai I, Ofran Y, Ganzel C, Zuckerman T, Okasha D, Hellmann I, Tadmor T, Dally N, Canaani J, Stemer G, Grunspan M, Berger AJ, Frankel N, Berelovich J, Bleterman A, Barak M, Cohen R, Moshe Y. Wolach O, et al. Blood Adv. 2025 Apr 8;9(7):1544-1554. doi: 10.1182/bloodadvances.2024014014. Blood Adv. 2025. PMID: 39637307 Free PMC article.
A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia.
Bang SY, Park S, Kwag D, Lee JH, Min GJ, Park SS, Yoon JH, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Lee JW, Kim HJ. Bang SY, et al. Cancers (Basel). 2023 Mar 8;15(6):1666. doi: 10.3390/cancers15061666. Cancers (Basel). 2023. PMID: 36980551 Free PMC article.
Selinexor Synergistically Promotes the Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia by Inhibiting Glycolytic Function and Downregulating the Expression of DNA Replication Genes.
Jiang J, Wang Y, Liu D, Wang X, Zhu Y, Tong J, Chen E, Xue L, Zhao N, Liang T, Zheng C. Jiang J, et al. Immunotargets Ther. 2023 Nov 23;12:135-147. doi: 10.2147/ITT.S429402. eCollection 2023. Immunotargets Ther. 2023. PMID: 38026089 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia

Affiliations

Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia

Authors

Affiliations

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Similar articles

Cited by

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical